Physician profile
Robert A Balk
NPI 1134173503
$46,759.89
in general payments reported to CMS, 2019-2025
9 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $9,450 · 2021: $19K · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $18,600.00 | 2021 | |
| Biomerieux INC | $11,561.75 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $10,279.26 | 2019-2020 | |
| Roche Diagnostics Corporation | $2,750.00 | 2020 | |
| Roche Molecular Systems, INC. | $2,535.88 | 2019 | |
| Astrazeneca Uk Limited | $1,000.00 | 2025 | |
| Paratek Pharmaceuticals, INC. | $33.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Balk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.